This country profile provides an overview of Liberia’s progress in reaching those in need of mass NTD treatment based on 2017 data.
*This includes all countries in Africa that are endemic for at least one of the five NTDs
Download country profile
Treatment coverage
Elephantiasis
84%
Blinding trachoma
N/A
Intestinal worms
96%
Bilharzia
38%
River blindness
84%
2.41 million
people received treatment in Liberia in 2017
0.18 million
people did not receive treatment in Liberia in 2017
Priorities for progress in Liberia
- Liberia is commended for the great progress made in the last two years in increasing its coverage for elephantiasis, river blindness and intestinal worms.
- As a priority, it should work to further build preventive chemotherapy for bilharzia in school age children, and systematically maintain high annual coverage across all of the diseases.
- Support the Expanded Special Project for Elimination of Neglected Tropical Diseases (ESPEN) established by WHO AFRO region for the elimination of these five diseases.
Elephantiasis
Treatment coverage increased from 74% in 2016 to 84% in 2017.
People needing treatment
2.38m
People receiving treatment
2m
Blinding trachoma
Liberia does not require mass treatment for blinding trachoma.
Intestinal worms
Treatment coverage increased from 90% in 2016 to 96% in 2017.
Pre-sch and school-aged children needing treatment
0.76m
Pre-school and school-aged children receiving treatment
0.73m
Bilharzia
Treatment coverage increased from 31% in 2016 to 38% in 2017.
School-aged children needing treatment
0.48m
School-aged children receiving treatment
0.19m
River blindness
Treatment coverage increased from 74% in 2016 to 84% in 2017.
People needing treatment
2.58m
People receiving treatment
2.17m
The 
ESPEN portal (a World Health Organization AFRO region project) provides maps and district-level data for the preventive chemotherapy diseases in Liberia.